Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL)
Objectives Patient experiences are critical when determining the acceptability of novel interventional pharmaceuticals. Here, we report the development and validation of a product acceptability questionnaire (SPRAY PAL) assessing feasibility, acceptability and tolerability of an intranasal Q-Griffit...
Main Authors: | Elizabeth Cash, Kailyn Deitz, Kevin L Potts, Henry W Nabeta, Maryam Zahin, Shesh N Rai, Gerald W Dryden, Kenneth E Palmer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/9/e073735.full |
Similar Items
-
Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin
by: Henry W. Nabeta, et al.
Published: (2021-10-01) -
Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis
by: Henry W. Nabeta, et al.
Published: (2022-10-01) -
Technoeconomic Modeling of Plant-Based Griffithsin Manufacturing
by: Aatif Alam, et al.
Published: (2018-07-01) -
Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01) -
Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential
by: Sabrina Lusvarghi, et al.
Published: (2016-10-01)